Table 4.
mRNA vaccine candidates for infectious diseases currently in clinical trials
| Sponsor(s)/Name | Virus type (Administration route) | Antigen type | Phase | Identifier | Status |
|---|---|---|---|---|---|
| ModernaTX, Inc./mRNA-1647 | CMV (i.m) | CMV pentamer and glycoprotein B | III | NCT05085366 | Recruiting |
| II | NCT04975893 | Enrolling by invitation | |||
| II | NCT04232280 | Active, not recruiting | |||
| I | NCT05105048 | Not yet recruiting | |||
| I | NCT03382405 | Completed | |||
| ModernaTX, Inc./mRNA-1443 | CMV (i.m) | CMV-associated | I | NCT03382405 | Completed |
| Massachusetts General Hospital, NIAID/Undefined | HIV (DC loaded, i.d) | HIV-associated | I/II | NCT00833781 | Completed |
| Fundacion Clinic per a la Recerca Biomédica/iHIVARNA-01 | HIV (DC loaded; i.nod) | HIV-associated with TriMix | II | NCT02888756 | Terminated |
| HIV (NA) | I | NCT02413645 | Completed | ||
| Argos Therapeutics/AGS-004 | HIV (DC EP; i.d) | HIV-associated Ag and CD40L | II | NCT00672191 | Completed |
| II | NCT01069809 | Completed | |||
| I/II | NCT00381212 | Completed | |||
| I | NCT02042248 | Completed | |||
| I | NCT02707900 | Terminated | |||
| ModernaTX, Inc./mRNA-1893 | Zika virus (i.m) | PrM-E | II | NCT04917861 | Recruiting |
| I | NCT04064905 | Completed | |||
| ModernaTX, Inc./mRNA-1325 | Zika virus (i.m) | PrM-E | I | NCT03014089 | Completed |
| ModernaTX, Inc./mRNA-1010 | Influenza A virus (H1N1 and H3N2 subtypes), Influenza B virus (Yamagata lineage, Victoria lineage) (i.m) | NA | I/II | NCT04956575 | Recruiting |
| ModernaTX, Inc./mRNA-1851(VAL-339851) | Influenza A virus (H7N9 subtype) (i.m) | H7N9 HA | I | NCT03345043 | Completed |
| ModernaTX, Inc./mRNA-1440 (VAL-506440) | Influenza A virus (H10N8 subtype) (i.m) | H10N8 HA | I | NCT03076385 | Completed |
| Translate Bio, Sanofi/MRT-5400 | Influenza A virus (H3N2 subtype) (i.m) | H3N2 HA | I | Unregistered | Unregistered |
| Translate Bio, Sanofi/MRT-5401 | Influenza A virus (H3N2 subtype) (i.m) | H3N2 HA | I | Unregistered | Unregistered |
| CureVac/ CV7201 | Rabies virus (i.d, i.m) | Rabies G protein | I | NCT02241135 | Completed |
| CureVac/ CV7202 | Rabies virus (i.m) | Rabies G protein | I | NCT03713086 | Active, not recruiting |
| GSK/ GSK3903133A | Rabies virus (i.m) | Rabies G protein | I | NCT04062669 | Active, not recruiting |
| ModernaTX, Inc./mRNA-1345 | RSV (i.m) | Stabilized prefusion F glycoprotein | I | NCT04528719 | Recruiting |
| ModernaTX, Inc./mRNA-1777(V171) | RSV (i.m) | Stabilized prefusion F glycoprotein | I | Unregistered | Unregistered |
| ModernaTX, Inc./mRNA-1172(V172) | RSV (i.m) | Stabilized prefusion F glycoprotein | I | Unregistered | Unregistered |
| ModernaTX, Inc./mRNA-1944 | Chikungunya virus (i.m) | Chikungunya mAb | I | NCT03829384 | Completed |
| ModernaTX, Inc./mRNA-1388(VAL-181388) | Chikungunya virus (i.m) | NA | I | NCT03325075 | Completed |
| ModernaTX, Inc./mRNA-1653 | hMPV (i.m) | Fusion proteins of hMPV and PIV3 | I | NCT04144348 | Recruiting |
| I | NCT03392389 | Completed |
CMV: cytomegalovirus; HIV: human immunodeficiency virus; NIAID: National Institute of Allergy and Infectious Diseases; DCs: dendritic cells; NA: not applicable; EP: electroporated; HA: hemagglutinin; GSK: GlaxoSmithKline; RSV: Respiratory syncytial virus; mAb: monoclonal Antibody; hMPV: human metapneumovirus; PIV3: parainfluenza virus type 3; i.m: intramuscular; i.d, intradermal; i.nod, intranodal.